First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices. - Wikidata - wikimedia - TriplyDB

First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices.

First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices.

http://www.wikidata.org/entity/Q37297943

about

Reversal effect of adenovirus-mediated human interleukin 24 transfection on the cisplatin resistance of A549/DDP lung cancer cells.Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.

P2860

Q47430166-5AB98607-32CB-4BA5-A355-73681F56F247 Q55507456-B3C56036-F1A8-44F3-9E89-BC29AF11DDA6

P2860

First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices.

http://www.wikidata.org/entity/Q37297943

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

First-Line Treatment with Beva ...... Oncology Community Practices.

@en

First-Line Treatment with Beva ...... Oncology Community Practices.

@nl

type

label

First-Line Treatment with Beva ...... Oncology Community Practices.

@en

First-Line Treatment with Beva ...... Oncology Community Practices.

@nl

prefLabel

First-Line Treatment with Beva ...... Oncology Community Practices.

@en

First-Line Treatment with Beva ...... Oncology Community Practices.

@nl

P1433

Q37297943-125083F5-98D1-4243-AB2F-BE81D09F56FC

P1476

Q37297943-181D3704-545C-4C00-A002-51749E3D366C

P2093

Q37297943-4A8DB4AD-FB6B-4E11-A0EC-ACD3CDF66C33

Q37297943-4EC9286A-72BD-4673-BF05-27D0BE8356B9

Q37297943-726D4D99-7E43-43FE-8E7D-CB606B74C20E

Q37297943-809C5B0F-3C62-46A9-B127-3D5ED98A8ED1

Q37297943-858D1E34-9B14-49BD-94CE-2BD283610388

Q37297943-C762B779-D50F-4E85-804F-FD9B6805F354

Q37297943-DBB9A104-2DD0-4A2E-A5EF-8F9692293905

Q37297943-E7A60907-245D-4D11-B230-6A56795A2789

P2860

Q37297943-08CFD345-E2E4-4D8C-8424-2371D1B76598

Q37297943-12B4729C-264C-49F7-A692-0EBD88B04388

Q37297943-2A3E84F2-AB91-4A29-B5CC-0BFE206AC238

Q37297943-3095351B-13A0-4A2F-B135-976663552C58

Q37297943-449A67DD-DDF5-4D43-939C-512AE09A8C01

Q37297943-5EF215CE-F09C-4A88-A2B2-F609023724D9

Q37297943-7110E31B-0BBC-4AC6-8F2E-B384FE510AE0

Q37297943-76D79571-A073-4B81-BB0F-4164E61C6E94

Q37297943-826D7325-BF58-4985-98FC-886B73A3E3BA

Q37297943-8A857782-45A9-44B7-9A5A-622974A38161

P2888

Q37297943-0B7FEB6F-BD55-4B27-B0C2-2BF22D28AF1B

P304

Q37297943-1EE122D5-7FE8-4385-A8A6-666C10852BEC

P31

Q37297943-74413515-B86E-441C-AC63-49FB897AA730

P356

Q37297943-C8DD1078-C340-4DF4-B896-4857D1EBC3A4

P433

Q37297943-362F5AC2-1BC6-4436-913C-08C9DB3B2B40

P478

Q37297943-43EE9C70-E591-4809-BB54-EDBB2B5824D5

P577

Q37297943-39AD7FBD-CBF1-4ABE-B89E-C5AA846DA948

P698

Q37297943-12C2B846-3514-4427-A674-34A3BCAE541F

P921

Q37297943-2B787953-7AEC-4CC5-860C-261C09C086E7

P932

Q37297943-CC6ED319-E955-42CC-B22C-50AD632963CB

P356

S40801-016-0090-5

P1433

Drugs - real world outcomes

P1476

First-Line Treatment with Beva ...... Oncology Community Practices.

@en

P2093

Anna D Coutinho

http://www.w3.org/2001/XMLSchema#string

Arliene Ravelo

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Goertz

http://www.w3.org/2001/XMLSchema#string

Joanne Willey

http://www.w3.org/2001/XMLSchema#string

Mark R Green

http://www.w3.org/2001/XMLSchema#string

Michael Eaddy

http://www.w3.org/2001/XMLSchema#string

Orsolya E Lunacsek

http://www.w3.org/2001/XMLSchema#string

Sebastien J Hazard

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2015

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials

P2888

s40801-016-0090-5

P304

333-343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40801-016-0090-5

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27747837

http://www.w3.org/2001/XMLSchema#string

P921

P932

5042946

http://www.w3.org/2001/XMLSchema#string